NDAINTRAVENOUSPOWDERPriority Review
Approved
Jun 2016
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
4
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NETSPOT is a 68Gallium-DOTATATE radiopharmaceutical diagnostic agent approved in 2016 for PET imaging of somatostatin receptor-positive neuroendocrine tumors. It binds with high affinity to somatostatin receptor subtype 2 (SSTR2), which is overexpressed on malignant neuroendocrine cells, enabling detection and localization via positron emission tomography.
Peak5.9 years to LOE
Product is at peak commercial maturity with 8+ years post-approval; mature commercial infrastructure with stable field and marketing operations.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (4)
Comparison of Al18F-NOTA-LM3 With 68Ga-DOTATATE and 68Ga-NODAGA-LM3 PET/CT in Patients With Well-differentiated Neuroendocrine Tumors
Started Mar 2023
80 enrolled
Neuroendocrine Tumors
68Ga-DOTATATE PET/CT in Neuroendocrine Tumor
Started Apr 2014
100 enrolled
Neuroendocrine Tumors
68Ga-DOTATATE PET-CT for Diagnosis of Neuroendocrine Tumors (NETs)
Started Mar 2013
169 enrolled
Neuroendocrine Carcinoma
68Ga-DOTATATE PET/CT in Oncogenic Osteomalacia
Started Dec 2011
100 enrolled
Oncogenic OsteomalaciaMesenchymal Tumor
Career Relevance
Worked on NETSPOT at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.